Professor MORITA Akinori

 To overcome a dose-limiting toxicity in radiotherapy, the development of radioprotectors that protect normal tissues but not cancer tissues are expected to be developed based on molecular targetbased drugs. We have found a new strategy of the prevention of radiation injury by regulating p53��and further explore the mechanistic basis to improve the effectiveness of these radioprotectors by researching projects listed as follows :

1. Development of novel kind of radioprotectors that target DNA damage response pathways.
2. Molecular mechanisms of radiation sensitivities in mammalian tissue cells.
3. Reactive oxygen species��ROS��signaling in mammalian cells.
4. Development of combination drug that enhances the antitumor effect of anticancer drug.